Progestogens and venous thromboembolism among postmenopausal women using hormone therapy

Maturitas

Volumn 70, Issue 4, 2011, Pages 354-360

  Canonico, Marianne ^a,b   Plu Bureau, Genevive ^a,c   Scarabin, Pierre Yves ^a,b  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Hormone therapy; Postmenopausal women; Progestogens; Venous thromboembolism

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; ELCOMETRINE; ESTRADIOL; ESTROGEN; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR; PROMEGESTONE; RALOXIFENE; TIBOLONE; TRIMEGESTONE;

DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEMOSTASIS; HORMONAL THERAPY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; POSTMENOPAUSE; REVIEW; VENOUS THROMBOEMBOLISM;

ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; PROGESTINS; VENOUS THROMBOEMBOLISM;

EID: 80755163464     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.10.002     Document Type: Review

References (62)

1. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause, Society Menopause 10 2003 113 132
2. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333 (Pubitemid 34761611)
3. G.L. Anderson, M. Limacher, and A.R. Assaf Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712 (Pubitemid 38489892)
4. V. Olie, M. Canonico, and P.Y. Scarabin Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women Curr Opin Hematol 17 2010 457 463
5. P.Y. Scarabin, E. Oger, and G. Plu-Bureau Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432 (Pubitemid 36999704)
6. M. Canonico, E. Oger, and G. Plu-Bureau Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study Circulation 115 2007 840 845 (Pubitemid 46294724)
7. M. Canonico, A. Fournier, and L. Carcaillon Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study Arterioscler Thromb Vasc Biol 30 2010 340 345
8. C. Renoux, S. Dell'Aniello, and S. Suissa Hormone replacement therapy and the risk of venous thromboembolism: a population-based study J Thromb Haemost 8 2010 979 986
9. M. Canonico, G. Plu-Bureau, G.D. Lowe, and P.Y. Scarabin Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis BMJ 336 2008 1227 1231 (Pubitemid 351809317)
10. J.D. Curb, R.L. Prentice, and P.F. Bray Venous thrombosis and conjugated equine estrogen in women without a uterus Arch Int Med 166 2006 772 780
11. M.R. Vickers, A.H. MacLennan, and B. Lawton Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women BMJ 335 2007 239
12. N.E. Allen, K.K. Tsilidis, and T.J. Key Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition Am J Epidemiol 172 2010 1394 1403
13. R. Sitruk-Ware Pharmacological profile of progestins Maturitas 47 2004 277 283 (Pubitemid 38523308)
14. A. Nath, and R. Sitruk-Ware Different cardiovascular effects of progestins according to structure and activity Climacteric 12 Suppl 1 2009 96 101
15. R. Sitruk-Ware New progestogens: a review of their effects in perimenopausal and postmenopausal women Drugs Aging 21 2004 865 883 (Pubitemid 39487071)
16. E. Daly, M.P. Vessey, M.M. Hawkins, J.L. Carson, P. Gough, and S. Marsh Risk of venous thromboembolism in users of hormone replacement therapy Lancet 348 1996 977 980 (Pubitemid 26340751)
17. H. Jick, L.E. Derby, M.W. Myers, C. Vasilakis, and K.M. Newton Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens Lancet 348 1996 981 983 (Pubitemid 26340752)
18. S. Perez Gutthann, L.A. Garcia Rodriguez, J. Castellsague, and A. Duque Oliart Hormone replacement therapy and risk of venous thromboembolism: population based case-control study BMJ 314 1997 796 800
19. N.L. Smith, S.R. Heckbert, and R.N. Lemaitre Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis JAMA 292 2004 1581 1587 (Pubitemid 39314964)
20. M. Cushman, L.H. Kuller, and R. Prentice Estrogen plus progestin and risk of venous thrombosis JAMA 292 2004 1573 1580 (Pubitemid 39314963)
21. D.I. Fraser, M.L. Padwick, M.I. Whitehead, J. White, T.A. Ryder, and J. Pryse-Davies The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy Maturitas 11 1989 21 34 (Pubitemid 19076762)
22. R. Sitruk-Ware Progestogens in hormonal replacement therapy: new molecules, risks, and benefits Menopause 9 2002 6 15 (Pubitemid 34106159)
23. T. Simon, M. Beau Yon de Jonage-Canonico, and E. Oger Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism J Thromb Haemost 4 2006 71 76
24. M.E. de Gooyer, G.H. Deckers, W.G. Schoonen, H.A. Verheul, and H.J. Kloosterboer Receptor profiling and endocrine interactions of tibolone Steroids 68 2003 21 30 (Pubitemid 35422732)
25. S.R. Cummings, B. Ettinger, and P.D. Delmas The effects of tibolone in older postmenopausal women N Engl J Med 359 2008 697 708
26. P. Kenemans, N.J. Bundred, and J.M. Foidart Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial Lancet Oncol 10 2009 135 146
27. J. Conard, A. Basdevant, and J.L. Thomas Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol Fertil Steril 64 1995 957 962
28. C. Egarter, P. Geurts, E. Boschitsch, P. Speiser, and J. Huber The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women Acta Obstet Gynecol Scand 75 1996 386 393 (Pubitemid 26000156)
29. K.K. Koh, R. Mincemoyer, and M.N. Bui Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women N Engl J Med 336 1997 683 690 (Pubitemid 27102682)
30. P.Y. Scarabin, M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial Arterioscler Thromb Vasc Biol 17 1997 3071 3078 (Pubitemid 28016061)
31. E. Hoibraaten, I. Os, I. Seljeflot, T.O. Andersen, A. Hofstad, and P.M. Sandset The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study Thromb Res 98 2000 19 27 (Pubitemid 30114257)
32. H.J. Teede, B.P. McGrath, and J.J. Smolich Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis Arterioscler Thromb Vasc Biol 20 2000 1404 1409 (Pubitemid 30262946)
33. W.M. van Baal, J.J. Emeis, M.J. van der Mooren, H. Kessel, P. Kenemans, and C.D. Stehouwer Impaired procoagulant-anticoagulant balance during hormone replacement therapy?. A randomised, placebo-controlled 12-week study Thromb Haemost 83 2000 29 34 (Pubitemid 30045472)
34. F.P. Chen, N. Lee, Y.K. Soong, and K.E. Huang Short- and long-term effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women Chang Gung Med J 24 2001 431 439 (Pubitemid 32801020)
35. A. Demirol, C. Baykal, S. Kirazli, and A. Ayhan Effects of hormone replacement on hemostasis in spontaneous menopause Menopause 8 2001 135 140 (Pubitemid 32199679)
36. A. Gottsater, M. Rendell, U.L. Hulthen, E. Berntorp, and I. Mattiasson Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors J Intern Med 249 2001 237 246 (Pubitemid 32417786)
37. E. Hoibraaten, M.C. Mowinckel, H. de Ronde, R.M. Bertina, and P.M. Sandset Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial Br J Haematol 115 2001 415 420 (Pubitemid 34203511)
38. R.A. Lobo, T. Bush, B.R. Carr, and J.H. Pickar Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism Fertil Steril 76 2001 13 24 (Pubitemid 32600954)
39. M. Perera, N. Sattar, and J.R. Petrie The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study J Clin Endocrinol Metab 86 2001 1140 1143 (Pubitemid 32322994)
40. M.S. Post, J. Rosing, and M.J. Van Der Mooren Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women Br J Haematol 119 2002 1017 1023 (Pubitemid 35463828)
41. S.O. Skouby, J. Gram, L.F. Andersen, J. Sidelmann, K.R. Petersen, and J. Jespersen Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations Am J Obstet Gynecol 186 2002 969 977
42. E. Oger, M. Alhenc-Gelas, and K. Lacut Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial Arterioscler Thromb Vasc Biol 23 2003 1671 1676 (Pubitemid 37108215)
43. M.S. Post, M. Christella, and L.G. Thomassen Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women Arterioscler Thromb Vasc Biol 23 2003 1116 1121 (Pubitemid 36713570)
44. J.C. Stevenson, A. Oladipo, N. Manassiev, M.I. Whitehead, S. Guilford, and A.J. Proudler Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers Br J Haematol 124 2004 802 808 (Pubitemid 38365786)
45. P. Collins, M. Flather, B. Lees, R. Mister, A.J. Proudler, and J.C. Stevenson Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study Eur Heart J 27 2006 2046 2053 (Pubitemid 44412809)
46. M.Z. Taner, E. Ozpolat, and C. Taskiran Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study Maturitas 53 2006 267 273 (Pubitemid 43163062)
47. C.E. Bonduki, D.M. Lourenco, E.L. Motta, J.M. Soares Jr., M.A. Haidar, and E.C. Baracat Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women Clinics (Sao Paulo) 62 2007 553 560
48. J. Endrikat, M. Sandri, C. Gerlinger, A. Rubig, W. Schmidt, and M. Fortier A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight Eur J Contracept Reprod Health Care 12 2007 220 228 (Pubitemid 47347173)
49. L.A. Norris, J. Brosnan, J. Bonnar, J. Conard, C. Kluft, and M. Hellgren Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/dydrogesterone and estradiol (2 mg)/trimegestone Thromb Haemost 100 2008 253 260
50. S.O. Skouby, J.J. Sidelmann, L. Nilas, J. Gram, and J. Jespersen The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors Climacteric 11 2008 489 497
51. N.L. Smith, J.R. Wiley, and C. Legault Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) study Menopause 15 2008 1145 1150
52. G. Samsioe, and J. Hruska Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results Climacteric 13 2010 34 44
53. M. Canonico, M. Alhenc-Gelas, G. Plu-Bureau, V. Olie, and P.Y. Scarabin Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen Menopause 17 2010 1122 1127
54. J.J. Sidelmann, J. Jespersen, L.F. Andersen, and S.O. Skouby Hormone replacement therapy and hypercoagulability. Results from the prospective collaborative Danish climacteric study BJOG 110 2003 541 547 (Pubitemid 36694207)
55. U.H. Winkler, R. Altkemper, B. Kwee, F.A. Helmond, and H.J. Coelingh Bennink Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study Fertil Steril 74 2000 10 19 (Pubitemid 30427266)
56. L.A. Norris, M. Joyce, N. O'Keeffe, B.L. Sheppard, and J. Bonnar Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy Maturitas 43 2002 125 133 (Pubitemid 35217772)
57. K.K. Koh, J.Y. Ahn, and D.K. Jin Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study Arterioscler Thromb Vasc Biol 23 2003 1889 1894 (Pubitemid 37254880)
58. K.K. Koh, S.H. Han, M.S. Shin, J.Y. Ahn, Y. Lee, and E.K. Shin Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study Eur Heart J 26 2005 1362 1368 (Pubitemid 41373512)
59. A.L. Eilertsen, E. Qvigstad, T.O. Andersen, L. Sandvik, and P.M. Sandset Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation Maturitas 55 2006 278 287 (Pubitemid 44397354)
60. A.L. Eilertsen, S. Liestol, M.C. Mowinckel, H.C. Hemker, and P.M. Sandset Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system Thromb Haemost 97 2007 938 943 (Pubitemid 46939206)
61. A.L. Eilertsen, L. Sandvik, M.C. Mowinckel, T.O. Andersen, E. Qvigstad, and P.M. Sandset Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis Thromb Res 120 2007 371 379 (Pubitemid 46879904)
62. A. Demirol, S. Guven, E.S. Guvendag Guven, S. Kirazli, T. Gurgan, and A. Ayhan Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study Fertil Steril 87 2007 842 848 (Pubitemid 46550407)